Study S002282

Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01399645
Acronym: LIRAINS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: COMPLETED
Enrollment: 35
Start: 2011-05
Primary completion: 2014-06
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Interventions: DRUG:Liraglutide-metformin vs insulin-metformin
Results posted: FALSE

Registered primary outcomes

To determine liver fat fraction evolution induced by liraglutide and insulin [12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026754	Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Tang A, Diabetes care	2015	Randomized trial	PMID 25813773 DOI	cites ClinicalTrials.gov:NCT01399645; registry reference DERIVED:25813773